Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer.

ABSTRACT:

Background

[(18)F]fluorothymidine (FLT) has been proposed as a positron emission tomography (PET)-imaging biomarker of proliferation for breast cancer. The aim of this prospective study was to assess the feasibility of FLT-PET-CT as a technique for predicting the response to neoadjuvant chemotherapy (NAC) in primary breast cancer and to compare baseline FLT with Ki-67.

Methods

Twenty women with primary breast cancer had a baseline FLT-PET-CT scan that was repeated before the second cycle of chemotherapy. Expression of Ki-67 in the diagnostic biopsy was quantified. From the FLT-PET-CT scans lesion maximum and mean standardised uptake values (SUVmax, SUVmean) were calculated.

Results

Mean baseline SUVmax was 7.3, and 4.62 post one cycle of NAC, representing a drop of 2.

SUBMITTER: Woolf DK 

PROVIDER: S-EPMC4056049 | biostudies-literature | 2014 Jun

REPOSITORIES: biostudies-literature